Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions
Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions
复制标题
DOI：
10.1007/s10620-007-9755-y
复制
发表时间：
2007-09-01
影响因子：
3.1
通讯作者：
Wang, Jinfu
中科院分区：
文献类型：
--
作者：
Huang, Zhaohui;Li, Lihua;Wang, Jinfu
DNA甲基化是结直肠癌发生的关键机制。粪便DNA异常甲基化分析可能为大肠癌的无创检测提供新的策略。为了探索这种方法的可行性，我们评估了分泌型卷曲相关蛋白基因2（SFRP 2）的甲基化状态，从患者的粪便样本CRC相对于一系列健康人和良性结直肠疾病患者，使用甲基化特异性聚合酶链反应。在CRC、腺瘤、增生性息肉和溃疡性结肠炎患者中，SFRP 2甲基化的发生率分别为94.2%、52.4%、37.5%和16.7%。在24例正常人中，只有1例DNA甲基化。初步研究表明，在CRC和癌前病变患者的粪便中经常可以检测到异常甲基化SFRP 2。粪便DNA甲基化检测可能是一种简单，有前途的，非侵入性的筛查工具，结直肠肿瘤。
DNA methylation is a key mechanism of colorectal carcinogenesis. Analysis of aberrantly methylation in stool DNA might provide a novel strategy for noninvasive detection of colorectal cancer (CRC). To explore the feasibility of this approach, we have assessed the methylation status of secreted frizzled-related protein gene 2 (SFRP2) in stool samples from patients with CRC with respect to a series of healthy individuals and patients with benign colorectal diseases, using methylation-specific polymerase chain reaction. Methylated SFRP2 occurs in 94.2%, 52.4%, 37.5%, and 16.7% of patients with CRC, adenomas, hyperplstic polyps, and ulcerative colitis, respectively. Of the 24 normal individuals, only 1 revealed methylated DNA. The pilot study revealed that aberrant methylated SFRP2 could be detected frequently in stools from patients with CRC and precancerous lesions. Methylation testing of fecal DNA may be a simple, promising, and noninvasive screening tool for colorectal neoplasia.